SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Nusse Roeland

(Last) (First) (Middle)
614 MCKINLEY PL N E

(Street)
MINNEAPOLIS MN 55413

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp [ TECH ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/27/2022
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/27/2022 A 338 A $0 7,297 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Options (Right to Buy) $295.77 10/27/2022 A 865 (1) 10/27/2032 Common Stock 865 $0 865 D
Stock Options (Right to Buy) $201.64 10/24/2020 10/24/2029 Common Stock 2,011 2,011 D
Stock Options (Right to Buy) $255.69 10/28/2021 10/29/2030 Common Stock 1,507 1,507 D
Stock Options (Right to Buy) $101.19 10/26/2017 10/27/2026 Common Stock 3,985 3,985 D
Stock Options (Right to Buy) $125.05 10/25/2018 10/26/2027 Common Stock 3,125 3,125 D
Stock Options (Right to Buy) $179.84 10/24/2019 10/25/2028 Commo Stock 1,898 1,898 D
Stock Options (Right to Buy) $87.39 10/31/2013 10/30/2023 Common Stock 4,000 4,000 D
Stock Options (Right to Buy) $91.78 10/30/2014 10/30/2024 Common Stock 4,000 4,000 D
Stock Options (Right to Buy) $87.34 10/29/2016 10/28/2025 Common Stock 4,260 4,260 D
Stock Options (Right to Buy) $515.24 10/27/2022 10/28/2031 Common Stock 633 633 D
Explanation of Responses:
1. The option vests on the earlier of the one year anniversary of the grant date (10/27/2022) or the date of Bio-Techne's 2023 annual meeting of shareholders.
Brenda S. Furlow as Attorney-in-Fact for Roeland Nusse pursuant to Power of Attorney previously filed 10/31/2022
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.